Collecting duct of Bellini renal carcinoma with psoas muscle recurrence: A case report and review of literature

Abstract

Collecting duct carcinoma (CDC) is a rare type of renal carcinoma with an aggressive course and poor treatment response. Up to date, there are only few reports of CDC, which may be due to unrecognized or unfamiliarity of its features and characteristics. We report a case of CDC in a 63-year-old male who initially presented with localized disease, and developed psoas muscle metastasis 15 months after partial nephrectomy with good surgical margins. No guidelines currently exist for the management of CDC; however, aggressiveness of the disease warrants close surveillance and consideration of adjuvant therapy even in patients with localized tumours. We postulate that CDC in its localized stage can be managed by partial nephrectomy, while preserving renal function; however, it is also important to consider a good oncologic outcome by administering adjuvant therapy, such as chemotherapy, and targeted therapy for a better prognostic outcome.

Collecting (Bellini) duct carcinoma: A clinical study of a rare tumour and review of the literature

“…Ansari and colleagues reported a response, with minimal side effects, to sorafenib in a patient with metastatic CDC. 22 Dason's review also indicated that immunotherapy is not effective in treating metastatic CDC, also there was no evidence to support the efficacy of targeted therapy, such as sunitinib or sorafenib, beyond small series or case reports.…”

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma

“…TKIs represent a valuable option for the treatment of metastatic ccRCC, however no results from CDC-specific prospective phase III trials are available so far. Retrospective data reported encouraging results on the activity of different TKIs including sunitinib, sorafenib, pazopanib, cabozantinib, and the mTOR inhibitor temsirolimus [32,[57][58][59]. The combination of sorafenib and chemotherapy with cisplatin plus gemcitabine reported an ORR of 30.8% and a disease control rate (DCR) of 84.6% in previously untreated mCDC patients [60].…”

Surgical monotherapy may be a suitable therapeutic strategy for advanced collecting (Bellini) duct carcinoma: A case report and literature review

“…It is cursory to state that all patients with CDC have a poor prognosis, as there have been reports of patients with CDC who have survived >5 years with controlled disease (4,7,13). Notably, none of these patients exhibited lymphadenopathy or metastasis prior to surgery and all received different therapies.…”